GLP-1 microdosing: what the labels and the rules say

GLP-1 microdosing is not an FDA-approved way to take any GLP-1. It means using semaglutide or tirzepatide below the doses on the drug’s label, and for Wegovy, Zepbound or the Wegovy pill that is off-label use. No clinical trial has shown that microdosing works for weight loss or that it is safe, and the weight-loss results on the labels come from the standard dose schedules. This guide covers what the labels’ lowest doses are for, what a prescriber can and can’t do, and the risks of splitting doses from pens and vials.

What “microdosing” means

There is no official definition. A 2026 commentary by two authors at the University of South Carolina College of Pharmacy, in Expert Opinion on Pharmacotherapy, describes it as using 25% to 50% of the maker’s recommended starting dose, or stretching the time between doses (Beck and Clements, 2026). The techniques it lists include “click counting” on multi-dose pens and extended-interval dosing.

The same commentary calls microdosing an off-label strategy that people try for fewer side effects, lower cost or easier access, and says high-quality evidence is “essentially absent”. It raises safety concerns about compounded products, non-standard ways of measuring doses and dosing accuracy.

It is off-label, and no trial supports it

When the FDA approves a drug, it approves a label: the conditions it treats, the doses and how to give them. The FDA explains that once a drug is approved, health care providers “generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient” (FDA). One of its own examples of off-label use is a drug “given in a different dose”.

The FDA adds the part that matters here: for an off-label use, the agency “has not determined that the drug is safe and effective”. The weight-loss trials behind Wegovy, the Wegovy pill and Zepbound tested the label’s dose ladders. Their results do not tell you what a microdose does.

The FDA suggests questions to ask a provider who proposes an off-label use, including what studies support it and whether it is likely to work better than an approved treatment.

The lowest doses on the labels, and why they exist

Every GLP-1 label starts low and steps up. These are the starting and maintenance doses:

Scroll sideways to see the full table

Sources: Wegovy label (rev. 06/2026), sections 2.2 and 2.3; Zepbound label (rev. 08/2026), sections 2.1 and 2.2.

The low starting doses are there to ease you in. Both labels say to follow the dose escalation “to reduce the risk of gastrointestinal adverse reactions”. Zepbound’s label goes further: the 2.5 mg dose “is for treatment initiation and is not approved as a maintenance dosage”. Staying on a starting dose for months is therefore outside the label too.

The labels already allow some flexibility, within approved doses:

• Wegovy injection. If a step is not tolerated, the label says to consider delaying the next increase by 4 weeks. Maintenance can be 1.7 mg instead of 2.4 mg.
• Wegovy pill. If a step is not tolerated, the next increase can be delayed. If 25 mg is not tolerated, the label suggests switching to the 1.7 mg weekly injection.
• Zepbound. Your clinician weighs response and tolerability in choosing a maintenance dose of 5, 10 or 15 mg, and if a maintenance dose is not tolerated, the label says to consider a lower one.

If side effects are the reason you are curious about microdosing, these options are the place to start. Our Zepbound side effects and Wegovy side effects guides show how often stomach effects happen at each dose.

What prescribers can and can’t do

A prescriber can:

• Prescribe an approved GLP-1 off-label, including at a lower dose, when they judge it medically appropriate for you.
• Use the flexibility built into the label: a slower climb, a longer stay at one step, or a lower maintenance dose.
• Prescribe a compounded GLP-1 for you as an individual patient. Since the shortages ended, a pharmacy may not regularly compound what the FDA considers essentially a copy of an approved drug, unless the prescriber determines and documents that a change makes a significant difference for that patient (FDA). Our guide to compounded semaglutide’s legal status explains the rules.

A prescriber can’t:

• Make an off-label dose FDA-approved, or point to a trial showing a microdose works.
• Change what a device is built to deliver. The pens and vials below come with their own instructions.
• Make a compounded product FDA-approved. Compounded semaglutide and tirzepatide are not Wegovy or Zepbound, and not generics of them. A compounding pharmacy prepares them, and they aren’t FDA-approved or reviewed by the FDA for safety, effectiveness or quality before they are sold.

The risks of splitting doses from pens and vials

Each approved device is built to deliver set doses, and each one’s Instructions for Use says how. Partial doses are not among them.

Zepbound KwikPen. It holds 4 fixed weekly doses. You turn the dose knob “all the way until it stops”, and the instructions say “Do not count clicks as you select the dose.” They also say “Do not inject the leftover medicine. Do not transfer ZEPBOUND from your Pen into a syringe.” The instructions warn that injecting what is left after 4 doses “could result in an incomplete dose”. Throw it away after 4 doses or 30 days after first use.

Wegovy single-dose pens. The instructions say “The dose of WEGOVY is already set on your pen.” Each pen is for one use, and once the needle cover locks you “cannot stop the injection and restart it later.”

Wegovy FlexTouch pen. It holds 4 doses of 2.4 mg, and “You can only select doses of 2.4 mg.” Its instructions say “Never use a syringe to withdraw medicine from your pen.”

Zepbound vials. A single-dose vial holds one 0.5 mL dose, and you throw away an opened vial after use “even if there is medicine left”. A multi-dose vial holds 4 doses of 0.6 mL and is thrown away after 4 doses or 30 days after first use. Always use a new syringe and needle.

Wegovy pill. Swallow it whole. The label says “Do not split, crush, chew or dissolve.”

The FDA has seen what goes wrong with measured doses. It has received reports of adverse events, some needing a hospital stay, that may be related to dosing errors with compounded semaglutide injections, where patients measured the wrong amount or providers miscalculated it (FDA). For multi-dose vials of compounded GLP-1s, the FDA recommends throwing the vial away 28 days after first use, even if medicine remains, and using a new sterile needle and syringe for every dose.

Never share a pen with another person, even with a new needle. Both labels warn that sharing can spread blood-borne infections.

A lower dose keeps the same warnings

A smaller dose is still the same drug. Wegovy and Zepbound carry a boxed warning for thyroid C-cell tumors seen in rodents, and neither is for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. The other label warnings, from pancreatitis to gallbladder disease, describe the drug as well. Tell your clinician your full history, including pregnancy plans, before any dose is set.

Questions to ask before you try it

• Is the dose you are proposing on the label, or off-label?
• If it is off-label, what evidence supports it for someone like me?
• Is the medicine FDA-approved, or compounded? If compounded, which pharmacy prepares it?
• How exactly will I measure each dose, with which syringe or device?
• What is the plan if I have side effects, or if I need a higher dose later?

Where compounded microdose plans fit

Some telehealth programs sell lower-dose plans of compounded semaglutide or tirzepatide, often called microdose plans. These are compounded products, not FDA-approved, and the doses are set by the prescriber rather than by an FDA label. If you are comparing them, our list of GLP-1 microdosing programs shows what each plan includes. For the trade-offs between compounded and brand-name tirzepatide, see compounded tirzepatide vs Zepbound.

The bottom line

GLP-1 microdosing is off-label use with no trial behind it. The labels’ lowest doses, 0.25 mg of Wegovy, 1.5 mg of the Wegovy pill and 2.5 mg of Zepbound, exist to ease you onto the drug and lower stomach side effects, and the labels already let a clinician slow the climb or choose a lower maintenance dose. Approved pens and vials are built for set doses, and their instructions rule out counting clicks or drawing medicine into a syringe. If you want a gentler start, talk to a licensed clinician about the options on the label first.